Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Filetti, S.; Durante, C.; Hartl, D.; Leboulleux, S.; Locati, L.D.; Newbold, K.; Papotti, M.G.; Berruti, A.; ESMO Guidelines Committee. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019, 30, 1856–1883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tuttle, R.M.; Haugen, B.; Perrier, N.D. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid 2017, 27, 751–756. [Google Scholar] [CrossRef] [PubMed]
- Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. Cancer J. Clin. 2017, 67, 93–99. [Google Scholar] [CrossRef]
- Lamartina, L.; Grani, G.; Arvat, E.; Nervo, A.; Zatelli, M.C.; Rossi, R.; Puxeddu, E.; Morelli, S.; Torlontano, M.; Massa, M.; et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2). Endocr. Relat. Cancer 2018, 25, L7–L11. [Google Scholar] [CrossRef] [Green Version]
- Tuttle, R.M.; Alzahrani, A.S. Risk stratification in differentiated thyroid cancer: From detection to final follow-up. J. Clin. Endocrinol. Metab. 2019, 104, 4087–4100. [Google Scholar] [CrossRef]
- Tuttle, R.M.; Tala, H.; Shah, J.; Leboeuf, R.; Ghossein, R.; Gonen, M.; Brokhin, M.; Omry, G.; Fagin, J.A.; Shaha, A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010, 20, 1341–1349. [Google Scholar] [CrossRef]
- Castagna, M.G.; Maino, F.; Cipri, C.; Belardini, V.; Theodoropoulou, A.; Cevenini, G.; Pacini, F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 2011, 165, 441–446. [Google Scholar] [CrossRef] [Green Version]
- Tuttle, M.; Morris, L.F.; Haugen, B.; Shah, J.; Sosa, J.A.; Rohren, E.; Subramaniam, R.M.; Hunt, J.L.; Perrier, N.D. Thyroid differentiated and anaplastic carcinoma. In AJCC Cancer Staging Manual, 8th ed.; Amin, M.B., Edge, S.B., Greene, F., Byrd, D., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., et al., Eds.; Springer International Publishing: New York, NY, USA, 2017; pp. 425–434. [Google Scholar]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.I.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [Google Scholar] [CrossRef] [Green Version]
- Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, pl1. [Google Scholar] [CrossRef] [Green Version]
- Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014, 159, 676–690. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- National Cancer Institute. 2019 SEER Cancer Statistics Review, 1975–2016. Available online: https://seer.cancer.gov/archive/csr/1975_2016/ (accessed on 16 June 2020).
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nikiforv, Y.E.; Biddinger, P.W.; Thompson, L.D.R. Diagnostic Pathology and Molecular Genetics of the Thyroid; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2009. [Google Scholar]
- Zhi, J.; Wu, Y.; Hu, L.; Zhao, J.; Liu, H.; Ruan, X.; Hou, X.; Zhang, J.; Zheng, X.; Gao, M. Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma. Int. J. Clin. Oncol. 2020, 25, 59–66. [Google Scholar] [CrossRef]
- Pontius, L.N.; Oyekunle, T.O.; Thomas, S.M.; Stang, M.T.; Scheri, R.P.; Roman, S.A.; Sosa, J.A. Projecting survival in papillary thyroid cancer: A comparison of the seventh and eighth editions of the American Joint Commission on Cancer/Union for International Cancer Control staging systems in two contemporary national patient cohorts. Thyroid 2017, 27, 1408–1416. [Google Scholar] [CrossRef]
- Van Velsen, E.F.S.; Stegenga, M.T.; van Kemenade, F.J.; Kam, B.L.R.; van Ginhoven, T.M.; Visser, W.E.; Peeters, R.P. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. Thyroid 2018, 28, 976–981. [Google Scholar] [CrossRef]
- Ghaznavi, S.A.; Ganly, I.; Shaha, A.R.; English, C.; Wills, J.; Tuttle, R.M. Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. Thyroid 2018, 28, 1293–1300. [Google Scholar] [CrossRef]
- Tam, S.; Boonsripitayanon, M.; Amit, M.; Fellman, B.M.; Li, Y.; Busaidy, N.L.; Cabanillas, M.E.; Dadu, R.; Sherman, S.; Waguespack, S.G.; et al. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid 2018, 28, 1301–1310. [Google Scholar] [CrossRef]
- Kim, M.; Kim, W.G.; Oh, H.S.; Park, S.; Kwon, H.; Song, D.E.; Kim, T.Y.; Shong, Y.K.; Kim, W.B.; Sung, T.Y.; et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid 2017, 27, 1149–1155. [Google Scholar] [CrossRef] [Green Version]
- Kim, M.; Kim, H.I.; Jeon, M.J.; Kim, H.K.; Kim, E.H.; Yi, H.S.; Kim, E.S.; Kim, H.; Kim, B.H.; Kim, T.Y.; et al. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study. Oral Oncol. 2018, 87, 97–103. [Google Scholar] [CrossRef]
- Shteinshnaider, M.; Muallem Kalmovich, L.; Koren, S.; Or, K.; Cantrell, D.; Benbassat, C. Reassessment of Differentiated Thyroid Cancer Patients Using the Eighth TNM/AJCC Classification System: A Comparative Study. Thyroid 2018, 28, 201–209. [Google Scholar] [CrossRef] [PubMed]
- Shaha, A.R.; Migliacci, J.C.; Nixon, I.J.; Wang, L.Y.; Wong, R.J.; Morris, L.G.T.; Patel, S.G.; Shah, J.P.; Tuttle, R.M.; Ganly, I. Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. Surgery 2019, 165, 6–11. [Google Scholar] [CrossRef] [PubMed]
- Chereau, N.; Oyekunle, O.T.; Zambeli-Ljepović, A.; Kazaure, H.S.; Roman, S.A.; Menegaux, F.; Sosa, J.A. Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system. Br. J. Surg. 2019, 106, 889–897. [Google Scholar] [CrossRef] [PubMed]
- Nam, S.H.; Bae, M.R.; Roh, J.L.; Gong, G.; Cho, K.J.; Choi, S.H.; Nam, S.Y.; Kim, S.Y. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma. Oral Oncol. 2018, 87, 158–164. [Google Scholar] [CrossRef] [PubMed]
- Tran, B.; Roshan, D.; Abraham, E.; Wang, L.; Garibotto, N.; Wykes, J.; Campbell, P.; Ebrahimi, A. An Analysis of the American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 2018, 103, 2199–2206. [Google Scholar] [CrossRef] [PubMed]
- Kim, K.; Kim, J.K.; Lee, C.R.; Kang, S.W.; Lee, J.; Jeong, J.J.; Nam, K.H.; Chung, W.Y. Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system. Ther. Adv. Endocrinol. Metab. 2020, 11, 2042018820921019. [Google Scholar] [CrossRef]
- Shi, X.; Liu, R.; Basolo, F.; Giannini, R.; Shen, X.; Teng, D.; Guan, H.; Shan, Z.; Teng, W.; Musholt, T.J.; et al. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J. Clin. Endocrinol. Metab. 2016, 101, 264–274. [Google Scholar] [CrossRef]
- Singer, P.A.; Cooper, D.S.; Daniels, G.H.; Ladenson, P.W.; Greenspan, F.S.; Levy, E.G.; Braverman, L.E.; Clark, O.H.; McDougall, I.R.; Ain, K.V.; et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch. Intern. Med. 1996, 156, 2165–2172. [Google Scholar] [CrossRef]
- Cooper, D.S.; Doherty, G.M.; Haugen, B.R.; Kloos, R.T.; Lee, S.L.; Mandel, S.J.; Mazzaferri, E.L.; McIver, B.; Sherman, S.I.; Tuttle, R.M.; et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16, 109–142. [Google Scholar] [CrossRef] [Green Version]
- Baldini, E.; Sorrenti, S.; Di Gioia, C.; De Vito, C.; Antonelli, A.; Gnessi, L.; Carbotta, G.; D’Armiento, E.; Miccoli, P.; De Antoni, E.; et al. Cervical lymph node metastases from thyroid cancer: Does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? BMC Clin. Pathol. 2013, 13, e7. [Google Scholar] [CrossRef]
Clinicopathological Parameters | No Recurrences | Recurrences | Cramer’s V Index | p-Value |
---|---|---|---|---|
Median age (range) | 47 year (12–80 year) | 48 (23–85 year) | - | 0.906 |
Age | ||||
≥55 year | 621 | 32 | - | 0.118 |
<55 year | 288 | 23 | ||
≥45 year | 419 | 25 | - | 0.926 |
<45 year | 490 | 30 | ||
Gender | ||||
Male | 192 | 24 | 0.125 | <0.001 |
Female | 717 | 31 | ||
AITD | ||||
Yes | 238 | 5 | 0.091 | 0.005 |
No | 671 | 50 | ||
PTC variants | ||||
classical | 545 | 16 | 0.291 | <0.001 |
follicular | 232 | 8 | ||
sclerosing | 84 | 23 | ||
tall cell | 21 | 7 | ||
T (7th edition) | ||||
T1–T2 | 716 | 12 | - | 0.028 |
T3–T4 | 193 | 9 | ||
T (8th edition) | ||||
T1a–T3a | 732 | 15 | 0.094 | 0.004 |
T3b–T4 | 177 | 11 | ||
N | ||||
N0 | 663 | 7 | 0.647 | <0.001 |
N1a | 71 | 3 | ||
N1b | 33 | 42 | ||
Stage (7th edition) | ||||
Stages I–II | 787 | 15 | - | 0.001 |
Stages III–IV | 120 | 10 | ||
Stage (8th edition) | ||||
Stage I | 844 | 18 | - | <0.001 |
Stages II–IV | 65 | 8 | ||
Multifocality | ||||
Yes | 208 | 8 | - | 0.412 |
No | 701 | 19 | ||
Capsular invasion | ||||
Yes | 197 | 11 | 0.077 | 0.019 |
No | 712 | 16 | ||
Muscle invasion | ||||
Yes | 76 | 7 | - | 0.015 |
No | 833 | 24 | ||
Vascular invasion | ||||
Yes | 46 | 5 | - | 0.013 |
No | 863 | 22 |
Cox Regression with TMN-8 | |||||
Clinicopathological Parameters | HR | 95% CI | p-Value | AIC | BIC |
Sex | 2.207 | 0.96–5.06 | 0.062 | 308.74 | 343.1 |
Histological variant | |||||
Classic | 1 | --- | --- | ||
Follicular | 0.57 | 0.16–2.03 | 0.387 | ||
Sclerosing | 2.22 | 0.81–6.08 | 0.122 | ||
Tall-cell | 4.08 | 1.12–15.10 | 0.035 | ||
Stage | 4.28 | 1.76–10.43 | 0.001 | ||
Cox Regression with TMN-7 | |||||
Clinicopathological Parameters | HR | 95% CI | p-Value | AIC | BIC |
Histological variant | 296.403 | 315.89 | |||
Classic | 1 | --- | --- | ||
Follicular | 0.66 | 0.18–2.37 | 0.524 | ||
Sclerosing | 2.43 | 0.88–6.69 | 0.085 | ||
Tall-cell | 4.31 | 1.17–15.83 | 0.028 | ||
Stage | 1.95 | 1.27–2.98 | 0.002 |
Cox Regression with TMN-8 | |||||
Clinicopathological Parameters | HR | 95% CI | p-Value | AIC | BIC |
Age (<55 year and ≥55 year) | 2.907 | 1.24–6.81 | 0.014 | 238.59 | 253.2 |
Lymph node metastasis | |||||
N0 | 1 | --- | --- | ||
N1a | 3.75 | 0.77–18.24 | 0.101 | ||
N1b | 37.55 | 14.79–95.34 | <0.001 | ||
Cox Regression with TMN-7 | |||||
Clinicopathological Parameters | HR | 95% CI | p-Value | AIC | BIC |
Age (<45 year and ≥45 year) | 3.5 | 1.16–10.55 | 0.026 | ||
Histological variant | 202.97 | 241.94 | |||
lassic | 1 | --- | --- | ||
Follicular | 1.53 | 0.37–6.29 | 0.556 | ||
Sclerosing | 3.42 | 1.04–6.69 | 0.042 | ||
Tall-cell | 7.22 | 1.69–30.80 | 0.008 | ||
T (T1–T2 and T3–T4) | 0.607 | 0.343–1.075 | 0.087 | ||
Lymph node metastasis | |||||
N0 | 1 | --- | --- | ||
N1a | 4.22 | 0.84–21.27 | 0.081 | ||
N1b | 34.72 | 10.43–115.601 | <0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sorrenti, S.; Carbotta, G.; Di Matteo, F.M.; Catania, A.; Pironi, D.; Tartaglia, F.; Tarroni, D.; Gagliardi, F.; Tripodi, D.; Watanabe, M.; et al. Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study. Cancers 2020, 12, 3637. https://doi.org/10.3390/cancers12123637
Sorrenti S, Carbotta G, Di Matteo FM, Catania A, Pironi D, Tartaglia F, Tarroni D, Gagliardi F, Tripodi D, Watanabe M, et al. Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study. Cancers. 2020; 12(12):3637. https://doi.org/10.3390/cancers12123637
Chicago/Turabian StyleSorrenti, Salvatore, Giovanni Carbotta, Filippo Maria Di Matteo, Antonio Catania, Daniele Pironi, Francesco Tartaglia, Danilo Tarroni, Federica Gagliardi, Domenico Tripodi, Mikiko Watanabe, and et al. 2020. "Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study" Cancers 12, no. 12: 3637. https://doi.org/10.3390/cancers12123637